profit from every $100 of sales.
$0$100
Alamar Biosciences
$31.84+13.51% today
+44.7% since Apr 13, 26
1-year low $19.091-year high $38.13
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2024 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Alamar Biosciences sold, what it kept, and what it did with the cash.
Sales went from $25.1 million in 2024 to $74.2 million in 2025, with -$29.8 million of profit last year.
SalesProfit
Alamar Biosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Alamar Biosciences | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Alamar Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2024 | 2025 |
|---|---|---|
| 25 | 74 | |
| 9 | 42 | |
| -50 | -31 | |
| -42 | -25 | |
| -47 | -30 | |
| -0.71 | -0.45 | |
| 34.2% | 56.2% | |
| -197.2% | -42.2% | |
| -187.2% | -40.2% |
Balance sheet
| In millions of USD | 2024 | 2025 |
|---|---|---|
| Total assets | 150 | 140 |
| Cash | 27 | 30 |
| Total debt | 33 | 41 |
| Total liabilities | 283 | 299 |
| -133 | -159 | |
| 67 | 67 | |
| – | – | |
| 35.3% | 18.8% |
Cash flow
| In millions of USD | 2024 | 2025 |
|---|---|---|
| -55 | -54 | |
| 3 | 6 | |
| -59 | -60 | |
| Dividends paid | – | – |
| – | – | |
| 1 | 3 |
Valuation
- –
- –
- –
- -8.3×
- 29.8×
- –
- –
- -2.7%
- -1.3%
- 0.0%
Profitability
- 56.2%
- -42.2%
- -40.2%
- -37.0%
- -26.5%
- 25.4%
- 18.8%
- -21.3%
- -27.0%
- 50.5%
Growth
- +195.2%
- –
- –
- –
- –
Financial health
- –
- -0.26
- 29.6%
- -78.1×
- 3.99
- 2.37
- 0.53
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 18%of 948
Bottom 8%of 871
Top 2%of 868
Bottom 27%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 8, 2026 | -1.74 | -1.71 | −1.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/6Passes 3 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
49No pass
Benjamin Graham
45No pass
Philip Fisher
63Pass
Peter Lynch
–Not enough data
Joel Greenblatt
2No pass
Charlie Munger
64Pass
Terry Smith
60Pass
Questions about Alamar Biosciences
Is Alamar Biosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 3 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Alamar Biosciences AI analysis
What does Alamar Biosciences do?
Alamar Biosciences is a commercial-stage proteomics company focused on ultra-sensitive, multiplexed protein detection for research and future clinical applications. It is in Biotechnology.
Does Alamar Biosciences pay a dividend?
No. Alamar Biosciences does not pay a dividend at the moment.
Is Alamar Biosciences stock halal?
Yes. Alamar Biosciences passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
Who are Alamar Biosciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Alamar Biosciences's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.